Sign up
Pharma Capital

ValiRx PLC making 'striking and important' progress on lead cancer compounds

Oliver de Giorgio-Miller, chairman of ValiRx Plc's (LON:VAL), tells Proactive Investors that their two lead cancer compounds are at stages in their development that they offer potential investors an investable proposition and an attractive offering to joint venture partners.

They’ve been given the green light to now expand the scope of the study around VAL201 – escalating the dosage with patients currently being recruited.

 

View full VAL profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.